ADMA Biologics reports $124.4 million in second-quarter revenue for 2026—a 2% increase year-over-year—and offers a brief business update. These figures point to modest yet steady growth in the current economic climate.

ADMA Biologics, Inc. has caught the attention of investors intrigued by its optimistic valuation metrics and forward-looking prospects. A recent bullish thesis proposes that the stock’s financial ratios, along with expert commentary, could be key indicators of future growth.